News Sanofi, Regeneron aim to undercut rivals with new RA drug New drug will be sold at around 30% discount to rivals.
News Sanofi beats expectations, driven by rare diseases and vacci... But sales of key insulin fall amid biosimilar competition.
News Report links Sanofi epilepsy drug with thousands of birth de... Depakine and generics linked with defects including spina bifida.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
